Society for Neuro-Oncology RSS Feed

30th Annual Meeting of the Japan Society of Brain Tumor Pathology on 24-May-12 8:30 AM

Thu, 24 May 2012 08:30:00 GMT

30th Annual Meeting of the Japan Society of Brain Tumor Pathology
Start Date: 24-May-12 8:30 AM
End Time: 26-May-12 5:30 PM
Location: Nagoya Congress Center, Atsuta-ku, Nagoya
Event Details:

JOINT EVENT: The 4th International Symposium of Brain Tumor Pathology

The 30th Annual Meeting of the Japan Society of Brain Tumor Pathology (JSBTP) and the 4th International Symposium of Brain Tumor Pathology (ISBTP) will be held from Thursday, May 24 to Saturday, May 26, 2012 at the Nagoya Congress Center.

The first scientific meeting of JSBTP was held in Nagoya in 1983 under the leadership of Dr. Yoichi Ishida (then Professor at the Department of Diagnostic Pathology, Gunma University Graduate School of Medicine) as President, and with the support mainly of Dr. Naoki Kageyama (then Professor at the Department of Neurosurgery, Nagoya University Graduate School of Medicine) and Dr. Jun Yoshida (then Assistant Professor at the Department of Neurosurgery, Nagoya University Graduate School of Medicine). The first meeting was held as a workshop and, from the 15th year, the meeting has been called the “Annual Meeting of the Japan Society of Brain Tumor Pathology.” (Dr. Kazuo Tabuchi, then Professor at the Department of Neurosurgery, Saga Medical School, served as President of the 15th annual meeting.) The membership has steadily increased every year and now exceeds 900. Annual meetings in the past were organized in various forms such as clinical pathology review meetings, educational seminars, and hands-on seminars. No other scientific organization has provided such a broad variety of programs specializing in tumor pathology.

The ISBTP is held once every few years concurrently with the JSBTP annual meeting. The second ISBTP was held in Nagoya in 2000 with Dr. Jun Yoshida (then Professor at the Department of Neurosurgery, Nagoya University Graduate School of Medicine) as President, concurrently with the 18th annual meeting of JSBTP. It was a milestone in the field of brain tumor pathology in Japan with many distinguished neuropathologists and neurosurgeons gathering from around the world to participate in the symposium. Subsequently, many significant achievements have been made in the field of brain tumor pathology, including a report of a new concept of brain tumors in the fourth edition of the WHO classification of brain tumors, changes in the classification of brain tumors due to the availability of genetic analysis brought by the development of molecular biological methods, and the emergence of new prognosis-associated factors such as MGMT and IDH1. After all these achievements, this meeting is an important opportunity for distinguished specialists in brain tumor pathology from around the world to gather again to discuss and review, face-to-face, the current issues and future perspectives in brain tumor pathology. Moreover, as always in our annual meetings, you can check slide glasses of many cases in the discussion under the microscope. Though the discussion may not reach a unified conclusion, all the participants have one thing in common ― the enthusiasm on brain tumor and its pathology.

Please plan to take advantage of all the unique opportunities that the 4th ISBTP and the 30th Annual meeting of JSBP will offer you.

Abstract Deadline February 29, 2012

For registration and conference information, please visit www.braintumor.jp/en/30th/index.html

Nagoya Congress Center

1-1 Atsuta-nishimachi

Atsuta-ku, Nagoya Japan

15th International Symposium on Pediatric Neuro-Oncology on 24-Jun-12 8:30 AM

Sun, 24 Jun 2012 12:30:00 GMT

15th International Symposium on Pediatric Neuro-Oncology
Start Date: 24-Jun-12 8:30 AM
End Time: 27-Jun-12 5:30 PM
Location: Sheraton Centre Toronto Hotel, Toronto, ON M5H 2M9
Event Details:

The International Symposium on Pediatric Neuro-Oncology (ISPNO) is a landmark, biennial event in paediatric medicine which will be held from June 24 - 27, 2012 at the Sheraton Centre Toronto Hotel.

Throughout this four-day symposium, attendees will engage in a multi-disciplinary curriculum and dialogue regarding new surgical treatments, innovative research and advances in paediatric neuro-oncology. This dynamic and interactive forum is designed to significantly expand the knowledge base of attendees and further enhance overall patient care worldwide. The program will feature plenary and poster sessions, as well as an Education Day and a Family Day.

Local Organizing Committee:
Eric Bouffet, Chair
Ute Bartels
David Eisenstat
Cynthia Hawkins
Annie Huang
Laura Janzen
Don Mabbott
Katrin Scheinemann
Uri Tabori

For additional information and registration, please visit www.ispno2012.com

Sheraton Centre Toronto Hotel

123 Queen Street West

Toronto, ON Canada M5H 2M9

10th Annual Meeting of the European Association of Neuro-Oncology on 6-Sep-12 8:30 AM

Thu, 06 Sep 2012 14:30:00 GMT

10th Annual Meeting of the European Association of Neuro-Oncology
Start Date: 6-Sep-12 8:30 AM
End Time: 9-Sep-12 5:30 PM
Location: Mondial & Cititravel Congresos
Event Details:

The French Society "Association des Neuro-Oncologues d’Expression Française ANOCEF" is very pleased and honored to welcome the 10th EANO 2012 conference in Marseille, and invites you to join this outstanding event for neuro-oncology in Europe and worldwide.

Increasing interest for neuro-oncology has been observed in recent years, related in part to increased knowledge of brain tumors and progress in diagnosis and therapies of these diseases. As a consequence, the EANO meeting exerts an increasing role by stimulating and giving access to research and knowledge in the different aspects of neuro-oncology. This educational and scientific event will give the opportunity to share and discuss the most up-to-date works in basic science, translational and clinical research, with an extended multidisciplinary approach that will cover among others biology, imaging, surgery, radiotherapy, chemotherapy and experimental therapies.

Marseille, European City of Culture in 2013, combines tradition and modernity with 26 centuries of history with Greek and Roman origins. Marseille constitutes an attractive place located in the South of France, opening to Provence history, landscapes and lifestyle and to the Mediterranean coast. Marseille has developed modern conference facilities with expanding success, reinforced by cultural and architectural landmarks and easy access to unforgettable sites such as Camargue, Luberon, Aix-en-Provence and the natural surroundings of Calanques forming hidden coves on the coast. ANOCEF will join its forces to the local organizing committee to do its very best to make your stay in Marseille fruitful, pleasant and memorable.

For registration details and additional information, visit www.eano2012.eu

Mondial & Cititravel Congresos

Rosselló, 303, àtic 1

Barcelona, SPAIN

2012 Chicago Multidisciplinary Symposium in Thoracic Oncology on 6-Sep-12 8:30 AM

Thu, 06 Sep 2012 13:30:00 GMT

2012 Chicago Multidisciplinary Symposium in Thoracic Oncology
Start Date: 6-Sep-12 8:30 AM
End Time: 8-Sep-12 5:30 PM
Location: Chicago Marriott Downtown, Magnificent Mile, Chicago, IL
Event Details:

Program Description
The 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology will offer valuable information on the multidisciplinary treatment approach for thoracic malignancies. This multidisciplinary meeting will promote interaction between the surgery, medical oncology and radiation oncology disciplines to achieve the best possible outcome for thoracic cancer patients. The meeting will also bring together physician specialists from around the world for interdisciplinary discussions on the latest research and state-of-the-art care for thoracic cancers.

Speakers will address a variety of strategies to treat lung and esophageal cancer, malignant mesothelioma and metastatic cancers of the chest. In addition, the symposium will highlight the translation of novel clinically significant discoveries into clinical practice. Other educational topics to be discussed include the relation of molecular diagnoses, pathology and the clinical significance of targeted therapies in molecularly defined patient subpopulations for clinical trials and clinical practice.

Program Content/Format
The content of the meeting has been organized by the Program Committee with representatives from the four co-sponsoring organizations: ASTRO, ASCO, IASLC and The University of Chicago.

The program includes:

•General Sessions featuring interdisciplinary speakers addressing topics chosen for their applicability in everyday practice.
•Interactive Sessions in which audience questions on common issues facing practitioners today will be answered by leaders in the field.
Scientific papers for oral and poster presentations.

Needs Statement
According to the American Cancer Society, nearly 226,160 Americans will learn they have lung cancer – the most common type of thoracic cancer – this year. Lung cancer is the number one cause of death from cancer each year for both men and women. This multidisciplinary meeting will promote interaction between medical oncologists, radiation oncologists and surgeons to achieve the best possible outcome for thoracic cancer patients.

There is a need for translation into clinical practice of novel clinically-significant discoveries, including molecular genotyping. Additional education is needed on topics related to molecular diagnoses, pathology and the clinical significance of targeted therapies in molecularly defined patient subpopulations for clinical trials and clinical practice.

Elements of Competence
This educational symposium has been designed to narrow the competency gaps of patient care, medical knowledge, work in interdisciplinary teams, evidence-based practice, quality improvement, professional standing and commitment to lifelong learning seven of the 15 core competencies embraced by the American Board of Medical Specialties, Accreditation Council for Graduate Medical Education and the Institute of Medicine.

Learning Objectives
At the conclusion of this activity, the learner will be able to:

•Recognize the clinical significance of molecular genotyping of lung cancer patients.

•Identify the most appropriate initial therapy for patients with advanced NSCLC including those with and without a specific genomic alteration.
•Discuss the recent advances in radiotherapy and surgical therapies for thoracic malignancies.
•Recognize the importance of a multidisciplinary approach to the care of all stages of patients with thoracic malignancies.

Target Audience
The meeting is designed for radiation, medical and surgical oncologists, nurses, diagnostic radiologists, pathologists, pulmonologists, scientists, residents-in-training, fellows and other health care professionals interested in the treatment, screening, evaluation and management of thoracic cancers.

For registration and additional conference information, please visit

www.thoracicsymposium.org

Chicago Marriott Downtown, Magnificent Mile

ASTRO Annual Meeting on 28-Oct-12 8:30 AM

Sun, 28 Oct 2012 12:30:00 GMT

ASTRO Annual Meeting
Start Date: 28-Oct-12 8:30 AM
End Time: 31-Oct-12 5:30 PM
Location: Boston Convention and Exhibition Center, Boston, MA
Event Details:

The theme for ASTRO's 54th Annual Meeting is Advancing Patient Care Through Innovation. Changing demographics, a physician based delivery system predicted by many to be unable to meet future demand, dramatic growth in science and technology transfer, shifts in patient attitudes and expectation, and all in the context of a health care delivery system that is becoming increasingly unaffordable represent important societal trends that will force change in how health care will be conceived and delivered. These trends will have untold effects on radiation oncology care as well. Many health policy experts see “innovation” as the solution for these challenges to our health care system—not only technological innovation, but innovation in the delivery of care—to achieve improved outcomes while bending the cost curve.

Program Objectives
At the conclusion of this activity, the learner will be able to:
- Examine the multidisciplinary care to improve patient outcomes.
- Describe the various trends that are impacting the delivery of medical care. – i.e. health policy, health economic, epidemiologic and demographic.
- Employ quality and safety measures in the delivery of radiation therapy.

Target Audience
This continuing medical education activity is designed to meet the interests of radiation oncologists, radiation oncology residents, radiation biologists, radiation physicists, dosimetrists, oncologists working in related specialties, radiation therapists, radiation oncology nurses, radiation oncology administrators and all other health professionals involved in the field of radiation oncology.

For registration and additional conference information, please visit

www.astro.org/annualmeeting

Boston Convention and Exhibition Center

SNO 17th Annual Scientific Meeting and Education Day on 15-Nov-12 8:00 AM

Thu, 15 Nov 2012 13:00:00 GMT

SNO 17th Annual Scientific Meeting and Education Day
Start Date: 15-Nov-12 8:00 AM
End Time: 18-Nov-12 12:00 PM
Location: Washington Hilton Hotel, Dupont Circle, Washington, DC 20009
Event Details:

This year's program will feature popular and informative plenary sessions, two informal poster sessions, a featured session on pediatric CNS tumors, and an Education Day. The Education Day will focus on targeted therapies and will include a special course on the basics of biomarkers, as well as a concurrent half-day session on quality of life.

Scientific Chair: E. Antonio Chiocca, MD, PhD

Education Day Co-Chairs: Balveen Kaur, PhD, Vinay Puduvalli, MD

Clinical Trials Course Chair: Susan Chang, MD

Quality of Life Co-Chairs: Michael Glantz, MD and Mary Lovely, PhD

Information:

Registration for the Scientific Meeting and Education Day includes continental breakfasts and boxed lunches each day, the Thursday evening welcome reception, two poster-viewing receptions and the main Saturday evening banquet.

If you require assistance with hearing, vision or mobility, or require a special diet, please contact Linda Greer.

Deadlines
The Pre-registration deadline for lowest registration rates is October 15.

The online registration deadline is November 12. Online registrations cannot be accepted after November 12. You will be required to register on on-site, and on-site surcharges will apply.

CANCELLATIONS must be received in writing no later than November 9; registration fees will be refunded less a $50 handling fee. Cancellations received after November 9 cannot be refunded, but the meeting registration can be transferred to another person with written authorization.

Washington Hilton Hotel, Dupont Circle

1919 Connecticut Ave., NW

Washington, DC USA 20009

SNO 17th Annual Scientific Meeting (NOT including Education Day) on 16-Nov-12 8:00 AM

Fri, 16 Nov 2012 13:00:00 GMT

SNO 17th Annual Scientific Meeting (NOT including Education Day)
Start Date: 16-Nov-12 8:00 AM
End Time: 18-Nov-12 12:00 PM
Location: Washington Hilton Hotel, Dupont Circle, Washington, DC 20009
Event Details:

This year's program will feature popular and informative plenary sessions, two informal poster sessions, and a featured session on pediatric CNS tumors.

Scientific Chair: E. Antonio Chiocca, MD, PhD

Education Day Co-Chairs: Balveen Kaur, PhD, Vinay Puduvalli, MD

Clinical Trials Course Chair: Susan Chang, MD

Quality of Life Co-Chairs: Michael Glantz, MD and Mary Lovely, PhD

Information:

Registration for the Scientific Meeting includes continental breakfasts and boxed lunches each day, the Thursday evening welcome reception, two poster-viewing receptions and the main Saturday evening banquet.

If you require assistance with hearing, vision or mobility, or require a special diet, please contact Linda Greer.

Washington Hilton Hotel, Dupont Circle

1919 Connecticut Ave., NW

Washington, DC USA 20009

Young Investigators Speed-Networking and Career Development Reception on 18-Nov-12 12:00 PM

Sun, 18 Nov 2012 17:00:00 GMT

Young Investigators Speed-Networking and Career Development Reception
Start Date: 18-Nov-12 12:00 PM
End Time: 18-Nov-12 2:30 PM
Location: Washington Hilton Hotel, Dupont Circle, Washington, DC 20009
Event Details:

Young Investigators Speed-Networking and Career Development Reception

This innovative and exciting new event is designed to promote and facilitate mentorship and collaboration within the neuro-oncology community. The reception will take place immediately following the end of the regular sessions of the SNO annual meeting, from 12:00pm to 2:30pm on Sunday, November 18.

Attendees will take part in an organized networking and mentoring session. Each participant will have the opportunity to interact with many potential collaborators and mentors for brief, high-value exchanges that will form the basis of mutually beneficial professional relationships. The organized session will be followed by an informal reception to allow for more extensive follow-up conversations. Lunch and refreshments will be available for registered participants.

There is no charge for this event, however participants must specifically register to confirm their attendance.

For additional questions or information, contact Linda Greer linda@soc-neuro-onc.org.

Washington Hilton Hotel, Dupont Circle

1919 Connecticut Ave., NW

Washington, DC USA 20009

Travel Scholarships Available for SNO Young Investigators to Attend the European Association of Neuro-Oncology Meeting

Chas Haynes - noemail@soc-neuro-onc.org — Tue, 24 Jan 2012 23:00:00 GMT

Travel scholarships available
for SNO young investigators to attend the biennial meeting of the
European Association of Neuro-Oncology
Marseille, France,September 6-9, 2012

Submission deadline: closed

This travel scholarship facilitates young clinicians and investigators who are within the first five years of their initial academic appointment to attend the biennial meeting of the European Association of Neuro-Oncology (EANO) to be held in Marseille, France, from September 6-9, 2012. A combined EANO/SNO committee will review submitted abstracts and will award two scholarships.

Scholarship recipients will present their research during an oral platform session of the EANO meeting. Scholarships will cover coach airfare, accommodation and full registration to the EANO meeting.

Submissions for travel scholarships will be accepted only via the on-line abstract site and will be reviewed by a combined EANO/SNO committee. The submission deadline is February 27, 2012.

The submission deadline was February 27, 2012, and is now closed.

24-Jan-12 5:00 PM

2012 Neuro-Tumor Club

Chas Haynes - noemail@soc-neuro-onc.org — Mon, 23 Jan 2012 19:00:00 GMT

18th Neuro-Tumor Club Dinner Meeting at AACR

Event Date: Monday April 2, 2012; 6:30–10:00pm
Location: Hotel Allegro, 171 W. Randolph, Chicago, IL

Meeting Chair: Jeffery Raizer, MD

The 18th Annual Neuro-Tumor Club Dinner Meeting was held during AACR in Chicago, IL, at the Allegro Hotel on April 19, 2012. The event was a great success with over 150 researchers in attendance.

As in past years, this event was an informal and stimulating exchange of late-breaking findings of specific and focused interest to investigators dedicated to brain tumor research.

A full meeting summary will be posted here shortly.

Tumor Club Format

A short introduction of the theme will be given by the moderators before the presentations. With only 5 slides to present, the purpose is that “each presenter will make a seminal observation, rebut dogma, disclose a paradox, or offer to crack open a new paradigm”. At the conclusion of each presentation we will have a short discussion. Think collaboration, new perspective, synergy, or a glimpse into your competitor’s lab. If you’ve written a recent review (or are planning to do so) on any of these themes, please offer to give a 3-minute introduction to the topic. Also, if there is a theme you would like to see developed, please feel free to suggest it.

Targeted Themes

1. Geno/Phenotyping and Personalized/Combinatorial Therapy
2. Angiogenesis and Tumor Microenvironment
3. New Gene and Immunotherapy
4. New Tools and Translational Approaches
5. CNS Metastases
6. Biomarkers in Gliomas?
7. Stem Cells
8. Animal Models

Timeline

Deadline, submission of abstracts: Friday, March 2, 2012
Notification sent to selected presenters: Friday, March 16, 2012
Deadline, submission of .ppt files by presenters: Monday, March 26, 2012
Final RSVP for the Dinner Meeting: Monday, March 26, 2012
Neuro Tumor Club Dinner Meeting: Monday, April 2, 6:30-10:00pm

Questions? Contact: Linda Greer

23-Jan-12 1:00 PM

New Public Data Resource from the NIH Common Fund’s Epigenomics Program

Fri, 29 Jul 2011 12:00:00 GMT

Researchers in the Reference Epigenome Mapping Consortium, part of the NIH Common Fund’s Roadmap Epigenomics Program (http://commonfund.nih.gov/epigenomics), have begun creating a community resource of genome-wide epigenetic maps in a variety of human primary cell and tissue types. The data currently represent more than 100 samples including adult and fetal cells and tissues, and embryonic and induced pluripotent stem cells. The majority of reference epigenomes being generated contain information about DNA methylation, a core set of histone modifications, chromatin accessibility, and gene expression. A subset of reference epigenomes will also contain an expanded set of at least twenty additional histone modifications. The Consortium’s website (http://roadmapepigenomics.org) provides information about protocols developed by Consortium members, information about data standards, and links to a variety of sites where the epigenomic data can be visualized in a genome browser or downloaded for subsequent analysis

29-Jul-11 7:00 AM

Neuro-Oncology’s New Impact Factor is 5.483

Chas Haynes - noemail@soc-neuro-onc.org — Thu, 30 Jun 2011 15:00:00 GMT

The Society for Neuro-Oncology is pleased to announce that the impact factor for our official journal, Neuro-Oncology, has increased by 10% to reach 5.483, in most recent Journal Citation Reports. This means that Neuro-Oncology has maintained its position as the premier journal in the field. The journal is now ranked 15th out of 185 titles in the clinical neurology category, and 24th out of 184 titles in oncology.

WK Alfred Yung, the journal's editor in chief commented: "I am delighted that Neuro-Oncology has achieved such a high impact factor this year, further cementing its position as the leading journal in the field. I’d like to thank our highly dedicated editorial team, authors and reviewers for their contributions and ongoing support, which enables us to provide the highest quality research to our readers.”

30-Jun-11 10:00 AM

Pediatric Neuro-Oncology Basic and Translational Research Conference Recap

Linda Greer - noemail@soc-neuro-onc.org — Thu, 06 Jan 2011 21:00:00 GMT

2011 Pediatric Neuro-Oncology Basic and Translational Research Conference

May 19-20, 2011, Loews Hotel, New Orleans, Louisiana

The 2011 Pediatric Neuro-Oncology Basic and Translational Research Conference took place at the Loews Hotel in New Orleans, Louisiana May 19-20, 2011. The Conference was made possible thanks to a generous grant from the Pediatric Brain Tumor Foundation (PBTF).

Some 200 clinicians, clinician-scientists, scientists, trainees and students attended this meeting. There were participants from over 13 countries around the world. There were platform and poster presenations in addition to Sunrise Sessions where attendees could “Meet the Experts” in the field. The Sunrise Sessions included topics such as diffuse intrinsic pontine glioma, molecular insights at the crossroads of neurodevelopment in tumorigenesis, translating the genomics of pediatric brain tumors into routine clinical practice, stem cells in pediatric brain tumors, and understanding treatment resistance and recurrence in pediatric brain tumors. A host of superb speakers was selected for these Sunrise sessions, and they were very well attended.

The Scientific Session on Thursday May 19^thwas divided into sessions on the genetics and basic biology of pediatric brain tumors, stem cells in translational therapeutics, pediatric brain tumor models and immunology, and high grade glioma and ependymomas. A major focus on the first day was on the BRAF fusion gene in tumors such as pilocytic astrocytoma. It has only been in the past 2 years that the importance of BRAF has been fully appreciated in pediatric brain tumors, and this Scientificd Session offered some of the latest research and models on this topic.

The session on stem cells covered neural progenitor cells in conditions like neurofibromatosis-1 model systems in mouse and tissue culture, and developmental pathway driven tumors such as the hedgehog pathway in medulloblastoma. The session on brain tumor models focused on medulloblastoma, pilocytic astrocytoma, and tumors found in tuberous sclerosis complex. An outstanding presentation was given on the creation of a novel pilocytic astrocytoma model in mice using activated activated BRAF. The afternoon session on high grade gliomas and ependymomas had research papers on angiogenesis, growth factor activating pathways including IGF-1R and PGF-Ra/b, and genomic alterations especially in ependymoma. A provocative presentation on screening of tumor neural stem cells revealed potential new treatments for ependymoma.

On Friday May 20^th, 2011 the day began with a Scientific Session on medulloblastoma, and several presentations were given which elucidated how far the research has gone with respect to increasing our understanding of the molecular biology of this particular tumor type. Large numbers of medulloblastoma samples have been analyzed in an international consortium that has provided the latest and most up to date genetic cataloging of major changes in medulloblastoma.

The late morning session continued on the theme of medulloblastoma, and research areas such as microRNAs, thrombospondin-1, SGK-1, FSTL5, FBWX7 and H1 were discussed with many of these genes serving as novel targets in this tumor.

From SNO, I should like to thank Fred Lang, President, Chas Haynes, Executive Director, Linda Greer and Jan Esenwein for all their assistance and encouragement. From the PBTF, I should like to thank Dianne Traynor, Executive Director and President, for her support, and continued interest in bringing together the best and brightest individuals working in the field of pediatric neuro-oncology.

The meeting was considered a great success, and a model of its kind for future meetings. Given how rapidly the field is changing, and how enthusiastic attendees were with this Conference, planning is now underway for the next meeting.

Dr. James T. Rutka

MD, PhD, FRCSC, FACS, FAAP, FAAN

RS McLaughlin Professor and Chair

Department of Surgery, University of Toronto

Co-Director, The Arthur and Sonia Labatt

Brain Tumour Research Centre

Professor

6-Jan-11 3:00 PM

2011 Pediatric Neuro-Oncology Basic and Translational Research Conference

Linda Greer - noemail@soc-neuro-onc.org — Thu, 22 Jul 2010 19:00:00 GMT

2011 Pediatric Neuro-Oncology Basic and Translational Research Conference

May 19-20, 2011

Loews Hotel, New Orleans, Louisiana

This meeting was held May 19-20, 2011, in New Orleans, Louisiana, and was a great success. Over 200 pediatric basic and translational scientists from twelve countries were in attendance to share the latest advances in the area of pediatric neuro-oncology. A full meeting recap will be posted shortly.

QUICK LINKS

OVERVIEW

The conference encouraged the sharing of ideas and results, new collaborations, and offered attendees a state-of-the-art update in the field of pediatric brain tumor research. To this end, the Scientific Program Committee created a highly informative and educational program from over 130 accepted abstracts..

The program featured popular and informative plenary sessions and informal poster sessions, as well as “Meet the Expert Sunrise Sessions”, at which attendees caught up with late breaking areas of research and controversies in the field.

This meeting was organized by the Society for Neuro-Oncology with the generous support of the Pediatric Brain Tumor Foundation.

LOCATION

The conference was held at the Loews Hotel, located only steps away from the world-famous French Quarter in New Orleans, Louisiana.

ABSTRACT SUBMISSION

Abstracts were accepted in the following categories:

Atypical Teratoid Rhabdoid Tumor (ATRT)

Basic Biology

Brainstem Tumors

Ependymoma

Immunology/Immunotherapy

Genetics/Epigenetics

Germ Cell Tumors

High Grade Gliomas

Medulloblastoma/PNETs

Pediatric Brain Tumor Models

Stem Cells
Signaling

Translational Therapeutics

SCIENTIFIC PROGRAM COMMITTEE

James Rutka, MD, PhD (Chair)

Mitchel Berger, MD

Darell Bigner, MD, PhD

David Eisenstat, MD

Jonathan Finlay, MD

Richard Gilbertson, MD, PhD
Frederick Lang, MD

Ian Pollack, MD

David Rowitch, MD, PhD

Timothy Van Meter, PhD

EDUCATIONAL OBJECTIVES

After attending the conference, participants should be able to

Perform molecular studies to characterize novel mutations important to pediatric CNS tumors (Knowledge, Competence, and Performance);
Apply innovative tumor analysis techniques to assess molecular response to therapy (Knowledge, Competence, and Performance);
Utilize novel in vitro and in vivo models of pediatric CNS tumors to test targeted therapies (Knowledge, Competence, and Performance);
Incorporate appropriate biomarker studies into clinical trial design for different pediatric CNS tumros to advance understanding of distinctive profiles that may influence therapy (Knowledge, Competence, and Performance).
Target Audience
This program is directed toward pediatric CNS tumor basic and translational scientists, and pediatric neuro-oncologists and medical oncologists.

Educational Methods
Lectures, Interactive Small Group/Breakout Sessions, Poster Sessions

Evaluation
A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Accreditation/Credit Designation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Texas MD Anderson Cancer Center and the Society for Neuro-Oncology. The University of Texas MD Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this educational activity for a maximum of 13.25 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

CME Certificates and Attendance Verification Certificates
Certificates awarding AMA PRA Category 1 CreditTM or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form.

Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.

Photographing, audiotaping, and videotaping are prohibited.

22-Jul-10 2:00 PM

2009-2010 Central Brain Tumor Registry of the US Statistical Report

Jan Esenwein - noemail@soc-neuro-onc.org — Sat, 20 Mar 2010 15:00:00 GMT

The Central Brain Tumor Registry of the United States (CBTRUS) announces the publication of its latest statistical report, 2009-2010 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006 (available online at www.cbtrus.org). Data collected by the National Program of Cancer Registries (CDC) and SEER (NCI) from 47 population-based cancer registries were analyzed resulting in an incidence rate of 18.71 cases per 100,000 person-years for all primary brain & central nervous system (CNS) tumors. CBTRUS estimates that 62,930 new cases of primary non-malignant and malignant brain and CNS tumors are expected to be diagnosed in the United States in 2010. Meningioma had the highest incidence and accounted for 33.8% of all primary brain tumors in 2004-2006. Gliomas, including glioblastoma, accounted for 32% of these tumors and 80% of all malignant brain tumors.

This Statistical Report continues the past efforts CBTRUS has made to provide accurate, population–based incidence rates for all primary brain and CNS tumors by histology, age, gender, race and Hispanic origin. As in previous reports, these data have been listed in histologic groupings with improved clinical relevance

Funding for the Central Brain Tumor Registry of the United States in 2008-2009 has been provided by the American Brain Tumor Association (www.abta.org) , the National Brain Tumor Society (www.braintumor.org) , the Pediatric Brain Tumor Foundation (www.pbtfus.org) and from the Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under contract # HHSN26100800766P.

Printed booklets may be requested by contacting cbtrus@aol.com.

20-Mar-10 10:00 AM

SNO Announces First International Outreach Fellowship Recipient

Chas Haynes - noemail@soc-neuro-onc.org — Tue, 24 Nov 2009 19:00:00 GMT

SNO International Outreach Research Fellowship
Supported by the American Brain Tumor Association and EMD Serono

The leadership of the Society for Neuro-Oncology and the SNO International Outreach Committee are pleased to announce that Dr. Yi Lin of China has been selected as the first SNO International Outreach Research Fellow.

This fellowship was made possible through the generous support of the American Brain Tumor Association and EMD Serono.

The purpose of this one-year fellowship is to provide a program for professionals from developing regions to perform clinical, translational or basic research in the area of pediatric or adult neuro-oncology in a clinical and/or laboratory setting in the United States or Canada.

Applications were reviewed based on the novelty and scientific merit of the proposed study and the credentials of the applicant, as well as the potential impact to the advancement of neuro-oncology in the applicant’s home country upon completion of the fellowship. The Tufts Medical Center has agreed to host Dr. Lin for the one-year Fellowship period where she will study under the supervision of Dr. Jay-Jiguang Zhu.

The call for applications for the next fellowship cycle will be announced in June, 2010, and details will be available on this website.

24-Nov-09 1:00 PM

2009 Joint Meeting Recap

Chas Haynes - noemail@soc-neuro-onc.org — Tue, 17 Nov 2009 21:00:00 GMT

This historic meeting, held at the Hilton New Orleans Riverside, New Orleans, Louisiana, on October 22–24, 2009, was the first joint meeting between the Society for Neuro-Oncology and the AANS/CNS Section on Tumors.

The meeting was a huge success, continuing the trend of years past with a record 600 abstracts presented and attendance of over 1,200 people. The meeting was co-chaired by Frederick Lang and Randy Jensen, assisted by a Scientific Committee composed of Abhijit Guha, Michael McDermott, Jeffrey Bruce, Susan Chang, Mark Gilbert, and Michael Vogelbaum, with Terri Armstrong organizing the Quality of Life sessions.The meeting benefitted from the generous sponsorship of many supporters this year. At the Leader level of corporate support were Bristol-Myers Squibb, Genentech, and Schering-Plough; at the Benefactor level were AstraZeneca, the CERN Foundation, and Exelixis; at the Supporter level, EMD Serono; and at the Contributor level, the Tug McGraw Foundation, and Eisai. The SNO Platinum-level supporters were the American Brain Tumor Association, Genentech, EMD Serono, Schering-Plough, the Pediatric Brain Tumor Foundation, and the Sontag Foundation.

In the traditional format of the yearly Society for Neuro-Oncology Meeting, the joint meeting started with an education half-day, with the theme of “Personalized Medicine: Is it the Future or Now?” The goals of this education half-day meeting were to explore the application of individual data to better target, prevent, and treat a particular disease or condition. During the session, the use of personalized clinical, radiographic, genomic, and protein data, as well as personalized epigenetics, was explored. Two speakers each representing the specialties of pathology, surgery, radiation oncology, and medical oncology discussed the technology in their subspecialty and the application of this technology towards personalized medicine. These talks addressed the current status of these applications and the future of personalized medicine. In the beginning session on neuropathology, Kenneth Aldape described the “Predictive and Prognostic Value of Global Profiling Technologies in Neuropathology.” He was followed by Daniel Brat, who spoke on the “Predictive and Prognostic Value of Specific Molecular Biomarkers in Neuropathology.” The surgical session began with Christopher Nimsky, who spoke on “Technology Supporting Personalized Surgical Care.” He was followed by Cameron Brennan, speaking on the topic of “Clinical Decision-making in Surgery Incorporating Molecular Markers.” This session was followed by a session featuring two radiation oncologists: Kristina Tsien, who spoke on the “Technology Supporting Personalized Radiation Oncology,” followed by Minesh Mehta, who discussed the “Role of Molecular Markers in Clinical Decision-making in Radiation Oncology.” The final speakers of the education half-day were Timothy Cloughesy, who spoke on “Molecular Markers for Guiding Decision-making in Personalized Neuro-oncology,” and Mark Gilbert, who discussed “Molecular Markers for Guiding Development of Clinical Trials and Personalized Neuro-oncology.”

Of note, the morning also included the special concurrent session on “Enhancing Quality of Life Throughout the Illness Trajectory.” This was organized by Terri Armstrong from the MD Andersen Cancer Center, Kimberly M. Wallgren from the CERN Foundation and Jennifer Brusstar from the Tug McGraw Foundation. To begin this session, attendees were treated to a moving video-taped welcome message from musician Tim McGraw, who expressed his appreciation to the organizers and participants for the important work they are doing on behalf of brain tumor patients. Walter Bail then discussed “Good News or Bad: Communicating with Your Patient,” and Jeffrey Wefel spoke on the topic of “Chemobrain? Impact of Tumor and Treatment on Neurocognitive Function: What We Know, Where to Go.” This was followed by talks on “Radiation of Brain Metastasis, Toxicity and Interventional Trials” by Paul Brown, “The Other Health Care Professional: Training the Care-giver” by Harriet Patterson, and “Promoting Comfort and Choice at the End of Life” by Sherry Fox.

The Joint Meeting of the Society for Neuro-Oncology and AANS/CNS Section on Tumors began on the afternoon of Thursday, October 22, with a moment of silence and remembrance in honor of Mike Traynor, President and Co-Founder of the Pediatric Brain Tumor Foundation, who had recently passed away. During the Introduction, notice was also made of the passing of Samuel Hassenbush, MD, PhD, for whom a talk later in the meeting was named.

The meeting then started with presentations of the top scoring abstracts. This session was composed of the eight top scoring abstracts of all of the abstracts submitted to the meeting. This preliminary session gave the general membership of the two Societies a chance to hear reports on a variety of great research, in both basic science and clinical research. During this session, the award for excellence in adult clinical research was given to Riccardo Soffietti for his paper, “Adjuvant Whole Brain Radiotherapy versus Observation after Radiosurgery or Surgical Resection of 1–3 Cerebral Metastases: Results of the EORTC 22952-26001 Study.” The award for excellence in adult translational research went to Aaron Tannenbaum for his paper, “Sunitinib Inhibits Glioma Growth by Blocking Progenitor Cell Recruitment.” The award for excellence in adult clinical research was presented to Mei-Yin Polley for the paper, “Six-month Progression-free Survival as an Alternative Primary Efficacy End-Point to Overall Survival in Newly-Diagnosed Glioblastoma Patients Receiving Temozolomide.”

The plenary sessions began with an open abstract session on Tumor Biology. Nine abstracts were presented in this session, and the award for excellence in adult basic research went to Lynette Moore for her paper “ IGFBP2 Is a Candidate Biomarker for INK4-ARF Status and a Therapeutic Target for High-Grade Gliomas.”

In the evening, a poster session and reception allowed attendees to mingle and review the incredible work being done by the members of the two Societies. The evening also included Satellite Symposia sponsored by companies with emerging technologies.

The following day began with sunrise sessions in which the topics of “Neurosurgical Oncological Endoscopy,” “Meningiomas: Current Basic Science and Clinical Treatments,” “Cancer Stem Cells; State of the Hypothesis” and “Metastatic Spine Tumors: Biology and Therapy” were addressed. In each of these sessions, a leader and three or four experts in the field discussed current issues related to the topic of their session.

The morning plenary session was begun with a presentation by the Farber Award winner, Peter Dirks. Dr. Dirks summarized his work on “Brain Tumor Stem Cells” and was well received. This was followed by an open abstract session on Medical Therapies.

After the open abstract session, the keynote speaker, Dr. Ramond Sawaya, addressed the topic of “Neurosurgical Oncology--an Indispensable Partner: Surgeons Can Be Involved in Neuro-oncological Research and Play an Important Role in the Neuro-Oncology Team.” After this interesting keynote address, the remainder of the afternoon was filled with concurrent open abstract sessions on the topics of Surgical Therapies; Experimental and Clinical Therapies; and Epidemiology and Quality of Life; Radiology; Pediatric Basic Science; Immunobiology and Immunotherapy; and Radiation Oncology. During the Epidemiology and Quality of Life session, the award for excellence in quality of life research went to Andrea Pace for her paper on “Palliative Home Care for Brain Tumor Patients: Results and Cost/Utility Analysis of 6 Years of a Pilot Project.” During the Pediatric Basic Science session, the award for excellence in pediatric basic research went to Robert Johnson for his paper on “Radial Glia Are Susceptible to Transformation into Ependymoma by Candidate Human Ependymoma Tumor Suppressor Genes (TSG) and Oncogenes.” The award for excellence in pediatric translational research went to Dominik Sturm for his paper on “Identification of SGK1 as a Novel Prognostic Marker for Disease Outcome in Medulloblastoma.”

That evening, during the second poster session, two awards were given for the best posters. A clinical poster award given to Gurpreet Kapoor from the University of Pennsylvania for his poster on the topic of “Perfusion-Weighted Imaging Identifies MR Surrogates of Malignant Glioma Molecular Subtypes.” A basic science award was given to Haizhong Feung from the University of Pittsburgh for research on the topic of “PDGFR Stimulates Glioma Cell Invasion Through Tyrosine Phosphorylation of a Bipartate Guanine Nucleotide Exchange Factor Dock180.”

As on Friday, Saturday morning began with early morning sunrise sessions in the format of “Meet the Experts.” In these well-attended sessions, the topics of “Epidemiology and Pharmacogenetics”; “Immunotherapy: Current Status of Clinical Trials”; “Medulloblastoma: Current State of Biology and Therapy”; and “-omics and Brain Tumors: Genomics, Proteomics, Metabolomics, Ubiquinomics” were addressed. The morning plenary sessions began with an introduction of the Hassenbusch Lecturer by Frederick Lang. This year’s Hassenbusch Lecturer was Katie Orrico, JD, who heads up the Washington Committee of the AANS/CNS. Ms. Orrico gave a wonderful talk that honored the accomplishments of Sam Hassenbush as well as outlined some of the difficulties facing neurosurgery in the upcoming health reform legislation.

The day concluded with plenary sessions on the topics of “Genomics and Proteomics,” “Stem Cells,” and “Pathological and Prognostic Markers.” The meeting adjourned at noon on Saturday, October 24, with a general consensus that combining the Tumor Section of the AANS/CNS Satellite Meeting and the Society for Neuro-Oncology Annual Meeting provided a wonderful platform for exchange of ideas between the two Societies. Many attendees expressed hope that this will be an ongoing recurring practice in the future.

17-Nov-09 3:00 PM

SNO Partners with Oxford Journals to Publish Neuro-Oncology

Chas Haynes - noemail@soc-neuro-onc.org — Thu, 05 Nov 2009 20:00:00 GMT

Oxford Journals and the Society for Neuro-Oncology (SNO) are pleased to announce a new publishing partnership.

Starting with the 2010 volume year, Oxford Journals will publish Neuro-Oncology, the highest ranked journal in its field with an Impact Factor of 5.0 in 2008.

As a result of this new partnership, SNO members and journal subscribers can look forward to a number of important improvements to the publication, including:

Doubling frequency from bimonthly to monthly publication,

Increased opportunities for publication of cutting-edge and timely clinical, translational and scientific data, and

Four-week lead time from manuscript acceptance to citable publication on-line.

Neuro-Oncology is the official journal of SNO. It has an international readership, and comprises peer-reviewed articles, reviews in all areas of neuro-oncology, symposia on selected topics, published abstracts of annual meetings, society news and announcements from around the world. The SNO leadership looks forward to working with Oxford Journals to ensure that Neuro-Oncology continues to be the leading journal in its field.

For more information on the journal, click here.

5-Nov-09 2:00 PM

2009 Joint Meeting of SNO and AANS/CNS Section on Tumors

noemail@soc-neuro-onc.org — Mon, 03 Aug 2009 18:00:00 GMT

The Society for Neuro-Oncology (SNO) and the AANS/CNS Section on Tumors are joining scientific research efforts to present the latest developments in neuro-oncology and tumor surgery at the 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors, October 22-24, 2009 in New Orleans, Louisiana. Register now for the most comprehensive review of cutting-edge laboratory and clinical research in the field of neuro-oncology and tumors! Register for the 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors today! The CNS is also offering special registration rates for Joint Meeting attendees who also register for the CNS Annual Meeting. Register through September 23, 2009 and you will receive up to 25% in savings on both meetings. In addition to this exclusive registration rate, the CNS is also offering a number of courses that members of the SNO and the AANS/CNS Section on Tumor attendees will find of value -...

About SNO

Wed, 16 May 2012 22:52:56 GMT

The Society for Neuro-Oncology is a multidisciplinary organization dedicated to promoting advances in neuro-oncology through research and education. Now in its seventeenth year, the Society continues to grow and mature as the premier North American organization for clinicians, basic scientists, nurses and other health care professionals whose focus is central nervous system tumors in children and adults. SNO Officers & Committees To view our 2011 Annual Report, click here. To view our 2010 Annual Report, click here. To view our 2009 Annual Report, click here. To view our 2008 Annual Report, click here. To view our 2007 Annual Report, click here. To view our 2007 Financial Audit, click here. The Society now has four programs-the Annual Meeting Sponsorship Program, the Partner's Advisory Council, the President's Club, and the Victor Levin Founder's Society- which sustain its vision and mission. The Annual...

2012 SNO Annual Scientific Meeting & Education Day

Wed, 16 May 2012 16:48:57 GMT

The 17th Annual Scientific Meeting and Education of the Society for Neuro-Oncology

November 15-18, 2012

Washington Hilton Hotel

Washington, DC

REGISTRATION IS NOW OPEN!

click here.

OVERVIEW

The program will feature popular and informative plenary sessions and informal poster sessions, as well as an Education Day, which this year will focus on targeted therapies and will include a special course on the basics of biomarkers. Education Day will also feature a concurrent half-day session on quality of life.

LOCATION

The 17th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology will be held November 15-18, 2012, at the Washington Hilton Hotel, in Washington, DC. SNO has negotiated a discounted rate of $189.00 per night for the duration of the conference. Rooms at the Hilton may be reserved on-line by clicking here.

EXHIBIT AND SUPPORT OPPORTUNITIES

A full prospectus for exhibit, support and ISS opportunities can be downloaded here.

TRAVEL SCHOLARSHIPS

Information will be posted mid-2012.

ABSTRACT SUBMISSION

The abstract submission system in now closed.

Accommodation

Mon, 14 May 2012 14:09:01 GMT

The 17th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology will be held at the Washington Hilton Hotel, in Washington, DC. SNO has negotiated a discounted rate of $189.00 per night for the duration of the conference. Rooms at the Hilton may be reserved on-line at

http://www.hilton.com/en/hi/groups/personalized/D/DCAWHHH-SNO-20121113/index.jhtml

**Event Template -left column - Quick Links

Thu, 10 May 2012 21:03:39 GMT

17th Annual SNO Meeting Registration Options

Thu, 10 May 2012 18:11:31 GMT

To register, please choose one of the following options:

SNO Annual Scientific Meeting and Education Day (Full Registration), November 15 - 18

SNO Annual Scientific meeting only (not including Education Day), November 16 - 18

Education Day only, November 15

International Outreach

Thu, 10 May 2012 17:04:33 GMT

International Outreach Research Fellowship Information International Outreach Research Fellowship - Host Institutions SNO International Outreach Research Fellowship With generous support from the American Brain Tumor Association (ABTA) and EMD Serono, the Society for Neuro-Oncology has established an International Outreach Research Fellowship. The purpose of this one-year fellowship is to provide a program for professionals from outside North America to perform clinical, translational or basic research in the area of pediatric or adult neuro-oncology in a clinical and/or laboratory setting in the United States or Canada. Applications are no longer being accepted for the 2012 fellowship cycle. Annual Meeting Travel Scholarships A total of eight $1500.00 scholarships were awarded for travel to the 16th Annual Scientific Meeting and Education Day in Garden Grove,...

*****home:spotlight

Fri, 27 Apr 2012 22:38:36 GMT

2012 International Outreach Research Fellowship

The application process for the 2012 award is now closed. This fellowship is made possible by generous support from the American Brain Tumor Association (ABTA) and EMD Serono. To review the eligibility criteria for the fellowship, click here.

International Outreach Research Fellowship

Fri, 27 Apr 2012 22:36:02 GMT

The SNO International Outreach Research Fellowship Supported by the American Brain Tumor Association and EMD Serono THE APPLICATION PROCESS FOR THE 2012 FELLOWSHIP IS NOW CLOSED. Purpose With generous support from the American Brain Tumor Association (ABTA) and EMD Serono, the Society for Neuro-Oncology has established a $50,000 International Outreach Research Fellowship. The purpose of this one-year fellowship is to provide a program for professionals from outside North America to perform clinical, translational or basic research in the area of pediatric or adult neuro-oncology in a clinical and/or laboratory setting in the United States or Canada. One fellowship award is made each year. Eligibility The fellowship is open to post graduate medical professionals working in the following areas: neurosurgery, neurology, radiation oncology, medical...

SNO Course on the Basics of Biomarkers 2012

Wed, 29 Feb 2012 18:56:05 GMT

SNO Course on the Basics of Biomarkers 2012 November 15, 2012 Washington, DC, Hilton Hotel Course directors: Susan Chang and Kenneth Aldape NIH has defined a biomarker as an objectively measured indicator of a biological or pathobiological process. There are many potential areas for which biomarkers can improve patient care that range from early detection and diagnosis, prediction of response or toxicity of therapy, and prognosis. Biomarkers can also potentially improve the efficiency of the development of novel treatment approaches. Despite years of research and numerous reports however, the number of markers that have emerged as clinically useful has been limited. Many early reports of promising biomarkers are often not replicated in larger subsequent studies. In this course, we review the definition and potential roles of biomarkers as it pertains to Neuro-Oncology, the various types of biomarkers, the importance of biostatistical considerations in the...

SNO Platinum Partners

Tue, 14 Feb 2012 21:58:00 GMT

The SNO Platinum Partners are part of SNO Foundation's Sustaining Partners Program.

The work we do at SNO would not be possible without the support of our Platinum Level Partners. Platinum Level Support allows us to sustain our Society of committed professionals and provide quality educational opportunities to our members. By demonstating their committment to SNO and the SNO mission, our Platinum Partners are able to reinforce their significant presence in the neuro-oncology field and strengthen lasting relationships with SNO members.

Benefits of Platinum Support include

Recognition at the “Platinum Level” on SNO materials throughout the year
Recognition in the SNO Annual Report and Business Meeting
Logo with hyperlink on homepage of the SNO website throughout the year
Display banner with company logo at Annual Meeting
On-site signage, and recognition slides during breaks at Annual Meeting
Named award presented to a SNO investigator
Six complimentary registrations to the SNO Annual Meeting
Seat on the SNO Partners Advisory Council

Total Support: $40,000 per year

For more information, please fill-out the contact form below.

Lorem ipsum survey

noemail@soc-neuro-onc.org — Fri, 20 Mar 2009 16:43:12 GMT

Objectives:

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diem nonummynibh euismod tincidunt ut lacreet dolore magna aliguam erat volutpat. Ut wisis enim ad minim veniam, quis nostrud exerci tution ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis te feugifacilisi.

Duis autem dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit au gue duis dolore te feugat nulla facilisi.

Ut wisi enim ad minim veniam, quis nostrud exerci taion ullamcorper suscipit lobortis nisl ut aliquip ex en commodo consequat. Duis te feugifacilisi per suscipit lobortis nisl ut aliquip ex en commodo consequat.Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diem nonummy nibh euismod tincidunt ut lacreet dolore magna aliguam erat volutpat.